Background: Cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a potential biomarker and therapy target for neurodegenerative diseases (NDDs). The purpose of this meta-analysis was to investigate the association between CSF sTREM2level and NDDs, and to reveal the dynamic changes in CSF sTREM2level in Alzheimer’s disease (AD) continuum. Methods: We systematically searched PubMed, Embase, Web of Science, and Cochrane Library databases for observational studies, which compared the levels of CSF sTREM2between NDDs and controls. Sources of heterogeneity were analyzed using sensitivity analysis, subgroup analysis and meta-regression. We assessed pooled data using a random-effects model. Results: Twenty-two observational studies which included 5716 participates were identified. Compared with the controls, the whole AD continuum group showed a significant increase in CSF sTREM2level (standardized mean difference [SMD]: 0.41, 95% confidence intervals [CI]: 0.24, 0.58,p< 0.001). The mild cognitive impairment (MCI) group displayed the largest effect size (SMD, 0.49 [95% CI: 0.10, 0.88],p= 0.014), followed by the AD cohort (SMD, 0.40 [95% CI: 0.18, 0.63],p< 0.001). The increase in sTREM2in the preclinical stage of AD (pre-AD) group was the lowest (SMD, 0.29 [95% CI: 0.03, 0.55],p= 0.031). Other NDDs also showed an increase in the CSF sTREM2levels compared with control groups (SMD, 0.77 [95% CI: 0.37, 1.16],p< 0.001). Conclusions: The pooled data confirmed that NDDs are associated with increased CSF sTREM2level, thereby suggesting the CSF sTREM2as a potential dynamic biomarker and therapy target for NDDs.